Financial PerformanceA surprise $18.3MM of Proleukin sales was reported, more than offsetting the Q2 miss.
Product LaunchThere is strong demand for Amtagvi, the launch is being well executed, and the momentum is building.
Revenue GuidanceManagement provided 2024 and 2025 sales guidance, which was bold and above expectations.